Nasdaq Biotechnology Ishares (IBB) 393.75 $IBB
Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target
Marketwired - Thu Jul 23, 8:01AM CDT
Vista Partners announced today that it has initiated coverage on Immune Pharmaceuticals Inc. (NASDAQ: IMNP); with a twelve-month price target of $6.00. Ross Silver, Principal Analyst at Vista Partners, stated, "Immune Pharmaceuticals Inc. ('IMNP'
, headquartered in New York, is a clinical stage biopharmaceutical company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. IMNP's lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with future studies planned for Crohn's disease, severe asthma, NASH and atopic dermatitis." Mr. Silver continues, "On July 14, 2015 Celgene Corporation (CELG) and Receptos, Inc. (RCPT) announced the signing of a definitive agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2B, net of cash acquired. The transaction adds Ozanimod, which has demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), among others. Having Receptos as a comparison may be beneficial to IMNP as we may now be able to understand from a monetary perspective the value a compound intended to treat UC amongst others is worth."
IBB: 393.75 (-0.60), IMNP: 1.86 (+0.02), CELGZ: 2.20 (-0.09)
iShares Nasdaq Biotechnology Index Fund (IBB) : Take profit @ $390
Trading Central - Wed Jul 15, 1:54PM CDT
A gravestone doji is taking place, calling for a trend reversal. We close our long position @ 390. Performance: +3.28%.
IBB: 393.75 (-0.60)
These 2 Biotech Stocks Cratered in 2015 -- Is 1 Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Wed Jul 15, 9:04AM CDT
Source: Cancer Institute of Columbia For the most part, biotech stocks have been having a great 2015. The iShares Nasdaq Biotech Index , for instance, has essentially clobbered the broader markets so far this year: Per usual, however,...
IBB: 393.75 (-0.60), AAVL: 16.16 (-0.34), PBYI: 98.75 (-1.25)
'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 95.44 (-1.60), FBT: 129.73 (-0.21), XBI: 265.02 (-2.52), AMGN: 164.10 (-0.15), IBB: 393.75 (-0.60), INTC: 28.59 (-0.01), CELG: 139.01 (+0.75), NFLX: 110.10 (-1.40), SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), KITE: 71.68 (-0.43), RCPT: 228.27 (-0.13), JUNO: 51.65 (-0.12), TWTR: 36.19 (+0.10), AAPL: 125.16 (-0.06), Z: 80.65 (-1.31)
As Biotech Beats, 6 Top ETF Picks For Rest Of 2015
at Investor's Business Daily - Tue Jul 14, 5:38PM CDT
Biotechnology and pharmaceutical ETFs powered ahead in the past month, handing profits-on-steroids to investors. A wave of mergers, robust pipelines and busier-than-ever hospitals continue to drive these industries forward. The iShares Nasdaq...
SPY: 210.18 (-1.19), EFAV: 67.03 (-0.17), OIL: 9.57 (-0.12), AGG: 109.14 (+0.31), ILMN: 219.94 (+2.45), IBB: 393.75 (-0.60), SHY: 84.77 (+0.01), VNQ: 77.74 (-0.98), FV: 25.27 (-0.12), SDY: 76.65 (-0.51)
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015 - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 8:30AM CDT
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015
XOP: 39.79 (+0.06), XT: 25.80 (-0.04), UBIO: 21.45 (-0.17), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), LABU: 54.25 (-1.46), ZBIO: 17.92 (+0.12), CHAD: 43.72 (-1.55), YLCO: 13.34 (-0.20), LABD: 26.32 (+0.74), DRIP: 71.00 (-0.10), ASHR: 44.30 (+1.28), GUSH: 19.75 (+0.14)
iShares Nasdaq Biotechnology Index Rises 1.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 13, 4:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 393.75 (-0.60)
Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 1.63% Yesterday
Comtex SmarTrend(R) - Mon Jul 13, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 393.75 (-0.60)
It's Time for Investors to Focus on Individual Stocks, Not Macro Events
at The Street - Mon Jul 13, 1:42PM CDT
The 'Fast Money Halftime' trading panel says that in this weak macro market, momentum stocks, individual companies and specific sectors should be the theme for investors, not broad-based index funds.
FIT: 46.20 (+0.67), GREK: 10.05 (-0.02), XBI: 265.02 (-2.52), C: 59.87 (-0.47), IBB: 393.75 (-0.60), BAC: 18.18 (-0.27), TLT: 121.09 (+1.49), MS: 39.94 (-0.60), NFLX: 110.10 (-1.40), SPY: 210.18 (-1.19), GS: 211.05 (-2.20), JPM: 69.64 (-0.44), QQQ: 112.20 (-0.42), DIA: 177.16 (-1.14), IWM: 123.57 (-1.38), XLF: 25.36 (-0.22)
Trader's Notebook: Transport ETF Could Bounce Back
at The Street - Thu Jul 09, 8:00AM CDT
The iShares Transportation Average ETF (IYT) has suffered in recent months, but may finally be nearing a bit of support.
YANG: 79.37 (+0.03), IBB: 393.75 (-0.60), YINN: 32.66 (-0.01), IYT: 145.53 (-3.11), FXI: 42.30 (-0.01)
iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 2.85%
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 393.75 (-0.60)
After Yesterday's Decline of 2.85%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 393.75 (-0.60)
3 Stocks to Buy in a Market Crash
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 08, 10:55AM CDT
The last five years have been an absolute dream particularly for biotech investors; shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) have scorched the returns of the market over that time period, up more than 400% when the...
ISIS: 55.08 (-0.30), GILD: 117.66 (+0.22), IBB: 393.75 (-0.60), CELG: 139.01 (+0.75)
Uncertainty Escalates After Greek Referendum
David Fry - at Seeking Alpha - Mon Jul 06, 11:14PM CDT
At this point words fail me once again. What will happen to Greece and their EU partners, no one knows. For now it's a cancer growing on both Greece and many world stock indexes. China is more alarming after the PBOC intervened in markets to no...
XLB: 46.09 (-0.68), GREK: 10.05 (-0.02), IBB: 393.75 (-0.60), EWO: 16.36 (-0.03), TLT: 121.09 (+1.49), EEM: 37.60 (-0.37), XLP: 49.96 (-0.19), SPY: 210.18 (-1.19), ITB: 27.78 (-0.21), IYR: 73.93 (-0.53), XLI: 53.60 (-0.50), SLV: 14.00 (-0.14), FXE: 107.93 (+0.76), XLF: 25.36 (-0.22), GDX: 13.62 (-0.46), JJC: 28.02 (-0.65), XLE: 70.87 (-0.06), FXI: 42.30 (-0.01), USO: 16.14 (-0.20), DBC: 16.27 (-0.14), DBA: 22.04 (-0.12), XLY: 78.85 (-0.47), FXY: 78.43 (+0.13), EZU: 38.84 (unch), XLU: 42.29 (-0.64), HAO: 28.59 (+0.15), UUP: 25.41 (-0.10), XRT: 98.79 (-1.28), XLV: 76.77 (-0.28), IEV: 44.71 (-0.13), GLD: 104.33 (-0.47), EPI: 22.18 (-0.20), RSX: 17.25 (-0.29), EFA: 64.60 (-0.17), EWZ: 29.22 (-1.24)
The Medicines Company Is Rallying Despite Unfavorable Ruling In Patent Case
Emerging Equities - at Seeking Alpha - Mon Jul 06, 6:51PM CDT
MDCO: 34.00 (+0.16), MYL: 66.56 (-1.34), IBB: 393.75 (-0.60)
Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th!
SA Editor Mike Taylor - Seeking Alpha - Thu Jul 02, 3:00PM CDT
A holiday-shortened week still left biotech investors with plenty to chew over. The start of a decade-long collaboration between Celgene ( CELG ) and Juno Therapeutics ( JUNO ) prompted a new wave of enthusiasm for an already well appreciated CAR-T...
CRMD: 3.44 (-0.16), SGYP: 8.42 (-0.14), MNK: 124.99 (-1.52), BIIB: 385.05 (-6.69), OCAT: 4.84 (-0.05), VRX: 253.84 (+14.92), PRGO: 189.71 (+0.66), VRTX: 130.85 (-0.17), GALT: 2.83 (+0.10), IBB: 393.75 (-0.60), MNKD: 5.42 (-0.04), HNT: 66.93 (+0.37), CELG: 139.01 (+0.75), CNC: 70.62 (-0.76), JNJ: 100.20 (+0.02), MDCO: 34.00 (+0.16), GILD: 117.66 (+0.22), GERN: 4.27 (-0.05), JUNO: 51.65 (-0.12), BXLT: 31.29 (-0.55), EXEL: 5.88 (-0.43), NVS: 103.05 (+1.75)
Gilead Sciences- A Rare Undervalued Company In A Frothy Biotech Market
William Koldus, CFA, CAIA - at Seeking Alpha - Thu Jul 02, 5:16AM CDT
SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), IBB: 393.75 (-0.60)
Deforestation Impacting Pharmaceutical Industry
Global Risk Insights - at Seeking Alpha - Tue Jun 30, 3:07PM CDT
Global rainforests hold unknown treasures for fighting and curing multiple diseases. But whilst the complete destruction of the world’s remaining rainforests looms on the horizon, pharmaceutical companies are only slowly beginning to tap this...
AZN: 66.55 (-0.67), PFE: 34.78 (-0.10), MRK: 58.07 (-0.06), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), SNY: 53.37 (+0.28), NVS: 103.05 (+1.75)
The Pharma Pipeline: Exploring An Underestimated Investment Theme
Manning & Napier - at Seeking Alpha - Tue Jun 30, 2:43PM CDT
Worldwide equity markets have had an impressive showing since emerging from the Great Recession. The run-up in prices has coincided with equities becoming broadly more expensive. Some regions offer more attractive opportunities than others from a...
XBI: 265.02 (-2.52), IBB: 393.75 (-0.60)
40% Return In ~4 Months With Our IP Selected Healthcare Companies Since SA Publication
Innovalpha - Seeking Alpha - Tue Jun 30, 10:48AM CDT
We wanted to know how the " 17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes " performed since SA publication on February 10th 2015, namely JAZZ, SAGE, TNXP, SGYP, ASPX, XNPT, INSM, RNN, NVDQ, ZSPH, ACUR, ICPT, RDHL,...
SGYP: 8.42 (-0.14), INSM: 26.22 (-0.36), RNN: 0.57 (-0.01), RDHL: 16.66 (-0.69), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), ACUR: 0.82 (-0.03), CORI: 13.95 (+0.22), SPNC: 24.83 (-0.84), SAGE: 75.18 (-1.80), TNXP: 8.62 (-0.42), EBIO: 2.91 (+0.01), HAE: 39.12 (-0.27), JAZZ: 186.34 (+1.97), ICPT: 280.00 (+10.69)
Vista Partners Initiates Coverage on Immune Pharmaceuticals Inc. (NasdaqCM: IMNP); $6.00 Price Target
Marketwired - Thu Jul 23, 8:01AM CDT
Vista Partners announced today that it has initiated coverage on Immune Pharmaceuticals Inc. (NASDAQ: IMNP); with a twelve-month price target of $6.00. Ross Silver, Principal Analyst at Vista Partners, stated, "Immune Pharmaceuticals Inc. ('IMNP'
, headquartered in New York, is a clinical stage biopharmaceutical company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. IMNP's lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with future studies planned for Crohn's disease, severe asthma, NASH and atopic dermatitis." Mr. Silver continues, "On July 14, 2015 Celgene Corporation (CELG) and Receptos, Inc. (RCPT) announced the signing of a definitive agreement in which Celgene has agreed to acquire Receptos. Under the terms of the merger agreement, Celgene will pay $232.00 per share in cash, or a total of approximately $7.2B, net of cash acquired. The transaction adds Ozanimod, which has demonstrated several areas of potential advantage over existing oral therapies for the treatment of ulcerative colitis (UC) and relapsing multiple sclerosis (RMS), among others. Having Receptos as a comparison may be beneficial to IMNP as we may now be able to understand from a monetary perspective the value a compound intended to treat UC amongst others is worth." IBB: 393.75 (-0.60), IMNP: 1.86 (+0.02), CELGZ: 2.20 (-0.09)
iShares Nasdaq Biotechnology Index Fund (IBB) : Take profit @ $390
Trading Central - Wed Jul 15, 1:54PM CDT
A gravestone doji is taking place, calling for a trend reversal. We close our long position @ 390. Performance: +3.28%.
IBB: 393.75 (-0.60)
These 2 Biotech Stocks Cratered in 2015 -- Is 1 Now a Buy?
George Budwell, The Motley Fool - Motley Fool - Wed Jul 15, 9:04AM CDT
Source: Cancer Institute of Columbia For the most part, biotech stocks have been having a great 2015. The iShares Nasdaq Biotech Index , for instance, has essentially clobbered the broader markets so far this year: Per usual, however,...
IBB: 393.75 (-0.60), AAVL: 16.16 (-0.34), PBYI: 98.75 (-1.25)
'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 95.44 (-1.60), FBT: 129.73 (-0.21), XBI: 265.02 (-2.52), AMGN: 164.10 (-0.15), IBB: 393.75 (-0.60), INTC: 28.59 (-0.01), CELG: 139.01 (+0.75), NFLX: 110.10 (-1.40), SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), KITE: 71.68 (-0.43), RCPT: 228.27 (-0.13), JUNO: 51.65 (-0.12), TWTR: 36.19 (+0.10), AAPL: 125.16 (-0.06), Z: 80.65 (-1.31)
As Biotech Beats, 6 Top ETF Picks For Rest Of 2015
at Investor's Business Daily - Tue Jul 14, 5:38PM CDT
Biotechnology and pharmaceutical ETFs powered ahead in the past month, handing profits-on-steroids to investors. A wave of mergers, robust pipelines and busier-than-ever hospitals continue to drive these industries forward. The iShares Nasdaq...
SPY: 210.18 (-1.19), EFAV: 67.03 (-0.17), OIL: 9.57 (-0.12), AGG: 109.14 (+0.31), ILMN: 219.94 (+2.45), IBB: 393.75 (-0.60), SHY: 84.77 (+0.01), VNQ: 77.74 (-0.98), FV: 25.27 (-0.12), SDY: 76.65 (-0.51)
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015 - Press Releases
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 8:30AM CDT
Zacks Investment Ideas feature highlights: The Best, Most Interesting ETFs to Launch in the First Half 2015
XOP: 39.79 (+0.06), XT: 25.80 (-0.04), UBIO: 21.45 (-0.17), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), LABU: 54.25 (-1.46), ZBIO: 17.92 (+0.12), CHAD: 43.72 (-1.55), YLCO: 13.34 (-0.20), LABD: 26.32 (+0.74), DRIP: 71.00 (-0.10), ASHR: 44.30 (+1.28), GUSH: 19.75 (+0.14)
iShares Nasdaq Biotechnology Index Rises 1.63% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 13, 4:09PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 393.75 (-0.60)
Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 1.63% Yesterday
Comtex SmarTrend(R) - Mon Jul 13, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $376.00 to a high of $380.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $372.86 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 393.75 (-0.60)
It's Time for Investors to Focus on Individual Stocks, Not Macro Events
at The Street - Mon Jul 13, 1:42PM CDT
The 'Fast Money Halftime' trading panel says that in this weak macro market, momentum stocks, individual companies and specific sectors should be the theme for investors, not broad-based index funds.
FIT: 46.20 (+0.67), GREK: 10.05 (-0.02), XBI: 265.02 (-2.52), C: 59.87 (-0.47), IBB: 393.75 (-0.60), BAC: 18.18 (-0.27), TLT: 121.09 (+1.49), MS: 39.94 (-0.60), NFLX: 110.10 (-1.40), SPY: 210.18 (-1.19), GS: 211.05 (-2.20), JPM: 69.64 (-0.44), QQQ: 112.20 (-0.42), DIA: 177.16 (-1.14), IWM: 123.57 (-1.38), XLF: 25.36 (-0.22)
Trader's Notebook: Transport ETF Could Bounce Back
at The Street - Thu Jul 09, 8:00AM CDT
The iShares Transportation Average ETF (IYT) has suffered in recent months, but may finally be nearing a bit of support.
YANG: 79.37 (+0.03), IBB: 393.75 (-0.60), YINN: 32.66 (-0.01), IYT: 145.53 (-3.11), FXI: 42.30 (-0.01)
iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 2.85%
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 393.75 (-0.60)
After Yesterday's Decline of 2.85%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jul 08, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $361.89 to a high of $370.75. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $365.85 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 393.75 (-0.60)
3 Stocks to Buy in a Market Crash
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jul 08, 10:55AM CDT
The last five years have been an absolute dream particularly for biotech investors; shares of the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) have scorched the returns of the market over that time period, up more than 400% when the...
ISIS: 55.08 (-0.30), GILD: 117.66 (+0.22), IBB: 393.75 (-0.60), CELG: 139.01 (+0.75)
Uncertainty Escalates After Greek Referendum
David Fry - at Seeking Alpha - Mon Jul 06, 11:14PM CDT
At this point words fail me once again. What will happen to Greece and their EU partners, no one knows. For now it's a cancer growing on both Greece and many world stock indexes. China is more alarming after the PBOC intervened in markets to no...
XLB: 46.09 (-0.68), GREK: 10.05 (-0.02), IBB: 393.75 (-0.60), EWO: 16.36 (-0.03), TLT: 121.09 (+1.49), EEM: 37.60 (-0.37), XLP: 49.96 (-0.19), SPY: 210.18 (-1.19), ITB: 27.78 (-0.21), IYR: 73.93 (-0.53), XLI: 53.60 (-0.50), SLV: 14.00 (-0.14), FXE: 107.93 (+0.76), XLF: 25.36 (-0.22), GDX: 13.62 (-0.46), JJC: 28.02 (-0.65), XLE: 70.87 (-0.06), FXI: 42.30 (-0.01), USO: 16.14 (-0.20), DBC: 16.27 (-0.14), DBA: 22.04 (-0.12), XLY: 78.85 (-0.47), FXY: 78.43 (+0.13), EZU: 38.84 (unch), XLU: 42.29 (-0.64), HAO: 28.59 (+0.15), UUP: 25.41 (-0.10), XRT: 98.79 (-1.28), XLV: 76.77 (-0.28), IEV: 44.71 (-0.13), GLD: 104.33 (-0.47), EPI: 22.18 (-0.20), RSX: 17.25 (-0.29), EFA: 64.60 (-0.17), EWZ: 29.22 (-1.24)
The Medicines Company Is Rallying Despite Unfavorable Ruling In Patent Case
Emerging Equities - at Seeking Alpha - Mon Jul 06, 6:51PM CDT
MDCO: 34.00 (+0.16), MYL: 66.56 (-1.34), IBB: 393.75 (-0.60)
Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th!
SA Editor Mike Taylor - Seeking Alpha - Thu Jul 02, 3:00PM CDT
A holiday-shortened week still left biotech investors with plenty to chew over. The start of a decade-long collaboration between Celgene ( CELG ) and Juno Therapeutics ( JUNO ) prompted a new wave of enthusiasm for an already well appreciated CAR-T...
CRMD: 3.44 (-0.16), SGYP: 8.42 (-0.14), MNK: 124.99 (-1.52), BIIB: 385.05 (-6.69), OCAT: 4.84 (-0.05), VRX: 253.84 (+14.92), PRGO: 189.71 (+0.66), VRTX: 130.85 (-0.17), GALT: 2.83 (+0.10), IBB: 393.75 (-0.60), MNKD: 5.42 (-0.04), HNT: 66.93 (+0.37), CELG: 139.01 (+0.75), CNC: 70.62 (-0.76), JNJ: 100.20 (+0.02), MDCO: 34.00 (+0.16), GILD: 117.66 (+0.22), GERN: 4.27 (-0.05), JUNO: 51.65 (-0.12), BXLT: 31.29 (-0.55), EXEL: 5.88 (-0.43), NVS: 103.05 (+1.75)
Gilead Sciences- A Rare Undervalued Company In A Frothy Biotech Market
William Koldus, CFA, CAIA - at Seeking Alpha - Thu Jul 02, 5:16AM CDT
SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), IBB: 393.75 (-0.60)
Deforestation Impacting Pharmaceutical Industry
Global Risk Insights - at Seeking Alpha - Tue Jun 30, 3:07PM CDT
Global rainforests hold unknown treasures for fighting and curing multiple diseases. But whilst the complete destruction of the world’s remaining rainforests looms on the horizon, pharmaceutical companies are only slowly beginning to tap this...
AZN: 66.55 (-0.67), PFE: 34.78 (-0.10), MRK: 58.07 (-0.06), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), SNY: 53.37 (+0.28), NVS: 103.05 (+1.75)
The Pharma Pipeline: Exploring An Underestimated Investment Theme
Manning & Napier - at Seeking Alpha - Tue Jun 30, 2:43PM CDT
Worldwide equity markets have had an impressive showing since emerging from the Great Recession. The run-up in prices has coincided with equities becoming broadly more expensive. Some regions offer more attractive opportunities than others from a...
XBI: 265.02 (-2.52), IBB: 393.75 (-0.60)
40% Return In ~4 Months With Our IP Selected Healthcare Companies Since SA Publication
Innovalpha - Seeking Alpha - Tue Jun 30, 10:48AM CDT
We wanted to know how the " 17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes " performed since SA publication on February 10th 2015, namely JAZZ, SAGE, TNXP, SGYP, ASPX, XNPT, INSM, RNN, NVDQ, ZSPH, ACUR, ICPT, RDHL,...
SGYP: 8.42 (-0.14), INSM: 26.22 (-0.36), RNN: 0.57 (-0.01), RDHL: 16.66 (-0.69), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), ACUR: 0.82 (-0.03), CORI: 13.95 (+0.22), SPNC: 24.83 (-0.84), SAGE: 75.18 (-1.80), TNXP: 8.62 (-0.42), EBIO: 2.91 (+0.01), HAE: 39.12 (-0.27), JAZZ: 186.34 (+1.97), ICPT: 280.00 (+10.69)
